12.1 Mechanism of Action Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelpar exerts its therapeutic effects in patients with PBC is not well understood. Pharmacological activity that is potentially relevant to therapeutic effects includes inhibition of bile acid synthesis through activation of PPARδ, which is a nuclear receptor expressed in most tissues, including the liver. Published studies show that PPARδ activation by seladelpar reduces bile acid synthesis through Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol.

indication

Primary Biliary Cholangitis (Primary Biliary Cirrhosis)

phase

marketed

seladelpar lysine

all catalysts(2)

News(0)

Patent cliff

patents (6)

FDA exclusivities (2)

Report a data issue

comments(0)

🐶 often sniffed alongside